Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Trial Details

NCT ID

NCT06576115

Phase

PHASE2

Sponsor

Barbara Ann Karmanos Cancer Institute

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• Nab paclitaxel
• Gemcitabine
• TheraBionic P1

Locations (sample)

• Clarkston, Michigan, United States|42.73586,-83.41883
• Detroit, Michigan, United States|42.33143,-83.04575
• Flint, Michigan, United States|43.01253,-83.68746
• Lansing, Michigan, United States|42.73253,-84.55553
• Lapeer, Michigan, United States|43.05142,-83.31883

Key Eligibility Criteria

• Patients must have histologically or cytologically proven advanced metastatic adenocarcinoma of the pancreas. Patients with mixed tumor with predom…
• One or more measurable metastatic tumors per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) on imaging studies CT or MRI or PET scans
• If female patient is of childbearing potential must have a negative serum pregnancy test (βhCG) documented up to 48 hrs prior to administration of …
• Females of childbearing potential and males with female partners of childbearing potential, if sexually active, must agree to use two forms of cont…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.